Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 15/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845322 | 0.90 | SLC16A1 (0.40) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL3832740 | 0.89 | SLC16A1 (0.54) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL4833778 | 0.88 | SLC16A1 (0.38) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL4833502 | 0.81 | SLC16A1 (0.43) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL4844053 | 0.79 | SLC16A1 (0.42) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL4845227 | 0.77 | SLC16A1 (0.53) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL4845224 | 0.77 | SLC16A1 (0.53) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL3831992 | 0.76 | SLC16A1 (0.50) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL3831990 | 0.76 | SLC16A1 (0.50) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5097011 | 0.72 | SLC16A1 (0.47) | SLC16A1CYP2C9CYP3A4SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221131-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-7393854-B2 | Thienopyrimidinedinones and their use in modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-07-01 | — | — | US | disclosed |
| US-20060135539-A1 | Thienopyridazinones and their use in modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221131-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN MODULATION OF AUTOIMMUNE DISEASE | TPMT, TYMP, TYMS | SLC16A1 4627/4885CYP2C9 374/4885CYP3A4 449/4885 |
| US-20060135539-A1 | Thienopyridazinones and their use in modulation of autoimmune disease | TBXA2R, PTGER2, TBXAS1 | SLC16A1 4795/4885CYP2C9 78/4885CYP3A4 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.